SCHEMBL24316097

SCHEMBL24316097

COC(=O)c1ccc(C(=O)NC(C)c2ccccc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.57
ALDH1A1 P00352 7/20 0.55
GAA P10253 2/20 0.55
PKM P14618 1/20 0.55
LMNA P02545 2/20 0.55
NPC1 O15118 1/20 0.55
ROCK2 O75116 5/20 0.53
ROCK1 Q13464 4/20 0.53
PRKG1 Q13976 2/20 0.53
RPS6KA5 O75582 1/20 0.53
MAP4K4 O95819 1/20 0.53
CDK1 P06493 1/20 0.53
CSF1R P07333 1/20 0.53
PRKACA P17612 1/20 0.53
FLT1 P17948 1/20 0.53
RPS6KB1 P23443 1/20 0.53
CDK2 P24941 1/20 0.53
AKT1 P31749 1/20 0.53
FLT4 P35916 1/20 0.53
KDR P35968 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29610471 0.88 P4HTM (0.58) MAPK1ALDH1A1GAAPKMLMNA
SCHEMBL26597834 0.88 P4HTM (0.58) MAPK1ALDH1A1GAAPKMLMNA
SCHEMBL16496342 0.78 BAZ2B (0.65) MAPK1ALDH1A1LMNANPC1ROCK2
SCHEMBL21226799 0.78 KDM4E (0.50) MAPK1ALDH1A1KDM4EL3MBTL1POLB
SCHEMBL20142362 0.78 KDM4E (0.50) MAPK1ALDH1A1KDM4EL3MBTL1POLB
SCHEMBL24316093 0.78 ALDH1A1 (0.57) MAPK1ALDH1A1GAAPKMLMNA
SCHEMBL20132427 0.78 KDM4E (0.50) MAPK1ALDH1A1KDM4EL3MBTL1POLB
SCHEMBL31314624 0.75 MAPK1 (0.74) MAPK1ALDH1A1NPC1KDM4EL3MBTL1
SCHEMBL28650145 0.75 MAPK1 (0.74) MAPK1ALDH1A1NPC1KDM4EL3MBTL1
SCHEMBL4398996 0.75 MAPK1 (0.74) MAPK1ALDH1A1NPC1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
CN-116783180-A Tricyclic ligands for degradation of IKZF2 or IKZF4 C4医药公司 2023-09-19 CN disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 MAPK1 2622/4885ALDH1A1 4344/4885GAA 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.